Key People/Management at Carrick Therapeutics

Timothy Pearson

Timothy Pearson

CEO
Ash Bahl

Ash Bahl

CSO
Jenny Horsfield

Jenny Horsfield

SVP Business Development
Stuart McIntosh

Stuart McIntosh

CMO
Ed Ainscow

Ed Ainscow

VP Biology
Paul McGee

Paul McGee

VP CMC Manufacturing
Show more

Carrick Therapeutics Office Locations

Carrick Therapeutics has offices in Dublin and Oxford
Dublin, IE (HQ)
Belfield
Oxford, GB
Magdalen Centre, Robert Robinson Ave
Show all (2)

Carrick Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Carrick Therapeutics total Funding

$95 m

Carrick Therapeutics latest funding size

$95 m

Time since last funding

5 years ago

Carrick Therapeutics investors

Carrick Therapeutics's latest funding round in October 2016 was reported to be $95 m. In total, Carrick Therapeutics has raised $95 m
Show all financial metrics

Carrick Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Carrick Therapeutics Online and Social Media Presence

Embed Graph

Carrick Therapeutics News and Updates

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor

Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021

DUBLIN, Ireland and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announces two presentations at the European Society for Medical Oncology (ESMO) Congress, to be held …

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

DUBLIN, Ireland and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samu…

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

DUBLIN, Ireland and BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samu…

Carrick Therapeutics Blogs

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2- Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

(DUBLIN, Ireland and BOSTON, Mass., August 16, 2021) – Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations to samuraciclib …

CARRICK THERAPEUTICS ANNOUNCES PLAN TO ESTABLISH US OPERATIONS AND APPOINTMENT OF TIM PEARSON AS CEO

DUBLIN, Ireland, 28 June 2019 Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it plans to establish business operations in Boston, Massachusetts, and the transition of leadership from…

Carrick Therapeutics in-licenses targeted ovarian cancer treatment from BTG and appoints George Golumbeski as Chairman

The post Carrick Therapeutics in-licenses targeted ovarian cancer treatment from BTG and appoints George Golumbeski as Chairman appeared first on Carrick Therapeutics.

Carrick Therapeutics Frequently Asked Questions

  • When was Carrick Therapeutics founded?

    Carrick Therapeutics was founded in 2015.

  • Who are Carrick Therapeutics key executives?

    Carrick Therapeutics's key executives are Timothy Pearson, Ash Bahl and Jenny Horsfield.

  • How many employees does Carrick Therapeutics have?

    Carrick Therapeutics has 24 employees.

  • Who are Carrick Therapeutics competitors?

    Competitors of Carrick Therapeutics include Taiho Oncology, TOT BIOPHARM and Celltrion Healthcare.

  • Where is Carrick Therapeutics headquarters?

    Carrick Therapeutics headquarters is located at Belfield, Dublin.

  • Where are Carrick Therapeutics offices?

    Carrick Therapeutics has offices in Dublin and Oxford.

  • How many offices does Carrick Therapeutics have?

    Carrick Therapeutics has 2 offices.